Independent register of U.S. FDA drug recalls · updated Oct 10, 2026
RxRecalls Get alerts
Class II · Moderate risk Ongoing Initiated Mar 13, 2025 (2 years ago)

Teriflunomide Tablets

Class II — Moderate risk. May cause temporary or reversible harm; serious harm unlikely.

Why it was recalled

CGMP Deviations

Cause type: cGMP deviation

Departures from current Good Manufacturing Practice found in production or during FDA inspection. A broad quality-system cause: the batch was made under conditions that fall short of FDA manufacturing standards. All cgmp deviation recalls.

What was recalled

Teriflunomide Tablets, 14mg, 30-count bottle, Rx Only, Manufactured by: Glenmark Pharmaceuticals Limited, Pithampur, Madhya Pradesh 454775, India, Manufactured for: Glenmark Pharmaceuticals Inc. USA, Mahwah, NJ 07430. NDC# 68462-424-30

Affected NDC 68462-0424-30

Compare with the code on your package — it is the most precise check available.

Product details

From the FDA NDC directory, for the product code this recall names. Compare with the label on your package.

ProductStrengthForm & routeLabelerType
teriflunomide
NDC 68462-0424
14 mg/1 Tablet, Film Coated
Oral
Glenmark Pharmaceuticals Inc., USA Rx
Recalling firm
Glenmark Pharmaceuticals Inc., USA
NDC code
68462-424-30
Origin
NJ, United States
Initiated by
Voluntary: Firm initiated
FDA recall number
D-0334-2025 · FDA notice

Check, then ask. Class II means harm is possible but usually temporary or reversible. Find the lot number on your package; if it matches, ask your pharmacist about a replacement. Do not simply stop a prescribed medication on your own - the gap can be riskier than the recall.

Other recalls by Glenmark Pharmaceuticals Inc., USA

All 2025 recalls
Class II · Moderate risk

Azelaic Acid Gel

CGMP Deviations: Product quality complaints concerning abnormal texture or consistency (described as grainy, gritty, or sandy) were received.

Ongoing cGMP deviation Glenmark Pharmaceuticals Inc., USA NDC 68462-626-52 D-0731-2026
Class II · Moderate risk

Alyacen 7/7/7

Failed Impurities/Degradation Specifications: This recall is being initiated due to out-of-specification results total impurities.

Ongoing Impurity / degradation Glenmark Pharmaceuticals Inc., USA NDC 68462-556-29 D-0588-2026
Class II · Moderate risk

Ondansetron Orally Disintegrating Tablets

Defective container: Preferred Pharmaceuticals received a letter from the manufacturer Glenmark, that the blister packs are not fully sealed and tablets falling out. Preferred Pharmaceuticals purchased the finished product and repackaged the product for sale.

Ongoing Packaging defect Glenmark Pharmaceuticals Inc., USA NDC 68462-157-13 D-0246-2026

Other cgmp deviation recalls from 2025

All cgmp deviation recalls
Class II · Moderate risk

TPN bag (patient specific)

Incorrect Product Formulation: product did not contain insulin as listed in the label.

Ongoing cGMP deviation Central Admixture Pharmacy Services, Inc (CAPS) Los Angeles D-0524-2026
Class II · Moderate risk

Toothpaste: a) COLGATE

CGMP Deviations: Insanitary conditions including rodent exposure/activity in their distribution center.

Ongoing cGMP deviation Gold Star Distribution INC D-0287-2026
Class II · Moderate risk

Deodorant: a) Axe

CGMP Deviations: Insanitary conditions including rodent exposure/activity in their distribution center.

Ongoing cGMP deviation Gold Star Distribution INC D-0286-2026